SELLAS Life Sciences Gr Q2 EPS $(0.31) Beats $(0.35) Estimate
Portfolio Pulse from Benzinga Newsdesk
SELLAS Life Sciences Gr (NASDAQ:SLS) reported Q2 losses of $(0.31) per share, beating the analyst consensus estimate of $(0.35) by 11.43%. This is a 24.39% increase over losses of $(0.41) per share from the same period last year.
August 10, 2023 | 8:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SELLAS Life Sciences Gr reported better than expected Q2 losses, which could positively impact the stock in the short term.
SELLAS Life Sciences Gr reported Q2 losses that were less than what analysts had predicted. This beat in earnings estimates is typically seen as a positive sign and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100